FOLFIRINOX for advanced pancreatic cancer

[1]  H. Kennecke,et al.  Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study , 2017, American journal of clinical oncology.

[2]  M. Zahir,et al.  Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[3]  S. Barni,et al.  FOLFIRINOX-Based Neoadjuvant Therapy in Borderline Resectable or Unresectable Pancreatic Cancer: A Meta-Analytical Review of Published Studies , 2015, Pancreas.

[4]  M. Bloomston,et al.  Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas , 2015, Annals of Surgical Oncology.

[5]  D. Cunningham,et al.  FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. , 2014, Clinical colorectal cancer.

[6]  F Levi,et al.  European cancer mortality predictions for the year 2014. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Keane,et al.  FOLFIRINOX in pancreatic cancer: Can results be reproduced outside the clinical trial setting? , 2014 .

[8]  T. Wilt,et al.  Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. , 2014, Journal of the National Cancer Institute.

[9]  R. Loungnarath,et al.  FOLFIRINOX in the real world setting: The multicentric experience of six Canadian institutions. , 2014 .

[10]  S. Maithel,et al.  Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma , 2013, Pancreas.

[11]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[12]  B. Dörken,et al.  Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy , 2013, Front. Oncol..

[13]  Jeffrey W. Clark,et al.  FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. , 2013, The oncologist.

[14]  C. la Vecchia,et al.  European cancer mortality predictions for the year 2014. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  T. Conroy,et al.  Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Lacy,et al.  FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity , 2013, Medical Oncology.

[17]  R. McWilliams,et al.  Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. , 2012, JOP : Journal of the pancreas.

[18]  Sharon M. Watanabe,et al.  The Edmonton Symptom Assessment System, a proposed tool for distress screening in cancer patients: development and refinement , 2012, Psycho-oncology.

[19]  M. Choti,et al.  Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent , 2012, Cancer.

[20]  M. Moore,et al.  Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Tuveson,et al.  Understanding Metastasis in Pancreatic Cancer: A Call for New Clinical Approaches , 2012, Cell.

[22]  C. Iacobuzio-Donahue,et al.  Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment Strategies , 2012, Cell.

[23]  K. Behrns.  FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer , 2012 .

[24]  G. Narayanan,et al.  A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma , 2012, BMC Cancer.

[25]  J. Tomlinson,et al.  Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery. , 2011, Archives of surgery.

[26]  G. Brandi,et al.  Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). , 2010, Oncology reports.

[27]  M. Moore,et al.  Evolution of systemic therapy for advanced pancreatic cancer , 2010, Expert review of anticancer therapy.

[28]  Kenneth J. Chang,et al.  Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement , 2009, Annals of Surgical Oncology.

[29]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Eduardo Bruera,et al.  The Edmonton Symptom Assessment System (ESAS): A Simple Method for the Assessment of Palliative Care Patients , 1991, Journal of palliative care.